化学免疫疗法
布鲁顿酪氨酸激酶
伊德里希
医学
临床试验
伊布替尼
威尼斯人
氟达拉滨
肿瘤科
美罗华
慢性淋巴细胞白血病
奥图穆马
靶向治疗
免疫学
酪氨酸激酶
内科学
白血病
抗体
化疗
癌症
环磷酰胺
受体
作者
Nitin Jain,William G. Wierda,Susan O’Brien
出处
期刊:The Lancet
[Elsevier]
日期:2024-07-26
卷期号:404 (10453): 694-706
被引量:33
标识
DOI:10.1016/s0140-6736(24)00595-6
摘要
The last decade has seen remarkable progress in our understanding of disease biology of chronic lymphocytic leukaemia (CLL) and the development of novel targeted therapies. Randomised clinical trials have reported improved progression-free survival and overall survival with targeted therapies compared with chemoimmunotherapy, and thereby the role of chemoimmunotherapy in todays' era for treatment of CLL is limited. Bruton tyrosine kinase (BTK) inhibitors, BCL2 inhibitors, and CD20 monoclonal antibodies have been established as appropriate therapy options for patients with CLL, both as the first-line treatment and in the treatment of relapsed or refractory CLL. Several ongoing phase 3 trials are exploring different combinations of targeted therapies, and the results of these trials might change the treatment framework in first-line treatment of CLL. Non-covalent BTK inhibitors, chimeric antigen receptor T-cell therapy, and other therapeutic strategies are being investigated in relapsed CLL. Some of the therapies used in relapsed CLL, such as non-covalent BTK inhibitors, are now being pursued in earlier lines of therapy, including first-line treatment of CLL.
科研通智能强力驱动
Strongly Powered by AbleSci AI